Skip to content
Companies

Elastrin Therapeutics

Nanoparticles that clear calcium from blood vessels

Raised to date

$500K

of $500K offered across 1 Form D filing

Investors
1
Last filed
Mar 11, 2025

About

Elastrin Therapeutics, Inc. is an innovative biotechnology company dedicated to creating groundbreaking therapies aimed at reversing cardiovascular diseases and reinstating elasticity in damaged tissues and organs. By addressing the genetic and environmental factors leading to the deterioration of elastin, the company seeks to enhance the quality of life for patients suffering from related health issues.

Elastrin’s unique focus on the restoration of elastin integrity positions it as a potential leader in addressing root causes of cardiovascular ailments rather than merely treating symptoms.

Funding

  • Security to be acquiredFiled Mar 11, 2025Form D/A
    $500K/ $500K

Product

ELT-001

Cardiovascular Therapy

ELT-001 is Elastrin Therapeutics' lead product candidate, featuring an innovative formulation of EDTA-loaded nanoparticles that are conjugated with a proprietary monoclonal antibody. This cutting-edge technology is designed to selectively target and eliminate harmful calcifications in areas where elastin has degraded, with the potential to significantly restore the elasticity of blood vessels and various organs.

  • Targeted delivery system via nanoparticle technology
  • Conjugation with a proprietary monoclonal antibody for enhanced efficacy
  • Removes calcification from degraded elastin sites

Built for

Patients with cardiovascular diseases, especially those with vascular calcification

People on file